113 related articles for article (PubMed ID: 16957152)
1. ERCC1 measurements in clinical oncology.
Reed E
N Engl J Med; 2006 Sep; 355(10):1054-5. PubMed ID: 16957152
[No Abstract] [Full Text] [Related]
2. DNA repair by ERCC1 in non-small-cell lung cancer.
Wilcox JE
N Engl J Med; 2006 Dec; 355(24):2590; author reply 2591. PubMed ID: 17171818
[No Abstract] [Full Text] [Related]
3. DNA repair by ERCC1 in non-small-cell lung cancer.
Cecere F; Bria E; Rosell R
N Engl J Med; 2006 Dec; 355(24):2590-1; author reply 2591. PubMed ID: 17167144
[No Abstract] [Full Text] [Related]
4. DNA repair by ERCC1 in non-small-cell lung cancer.
Grenader T; Shavit L
N Engl J Med; 2006 Dec; 355(24):2591; author reply 2591. PubMed ID: 17167936
[No Abstract] [Full Text] [Related]
5. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
Olaussen KA; Mountzios G; Soria JC
Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
[TBL] [Abstract][Full Text] [Related]
7. [ERCC1 expression and outcomes of neo-adjuvant chemotherapy in elderly patients with non-small cell lung cancer].
Li GF; Deng SJ; Weng WW; Guo G; Chen N
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Sep; 30(9):2131-3. PubMed ID: 20855270
[TBL] [Abstract][Full Text] [Related]
8. Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2.
Ko JC; Su YJ; Lin ST; Jhan JY; Ciou SC; Cheng CM; Chiu YF; Kuo YH; Tsai MS; Lin YW
Lung Cancer; 2010 Aug; 69(2):155-64. PubMed ID: 19962780
[TBL] [Abstract][Full Text] [Related]
9. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
Olaussen KA; Dunant A; Fouret P; Brambilla E; André F; Haddad V; Taranchon E; Filipits M; Pirker R; Popper HH; Stahel R; Sabatier L; Pignon JP; Tursz T; Le Chevalier T; Soria JC;
N Engl J Med; 2006 Sep; 355(10):983-91. PubMed ID: 16957145
[TBL] [Abstract][Full Text] [Related]
10. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
Vilmar A; Sørensen JB
Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
[TBL] [Abstract][Full Text] [Related]
11. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
12. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
Cobo M; Isla D; Massuti B; Montes A; Sanchez JM; Provencio M; Viñolas N; Paz-Ares L; Lopez-Vivanco G; Muñoz MA; Felip E; Alberola V; Camps C; Domine M; Sanchez JJ; Sanchez-Ronco M; Danenberg K; Taron M; Gandara D; Rosell R
J Clin Oncol; 2007 Jul; 25(19):2747-54. PubMed ID: 17602080
[TBL] [Abstract][Full Text] [Related]
13. [Histoculture drug response assay guided adjuvant chemotherapy in patients with ERCC1-positive non-small cell lung cancer].
Hirai Y; Yoshimasu T; Oura S; Tamaki T; Ota F; Nakamura R; Shimizu Y; Naito K; Ota M; Miyasaka M; Okamura Y; Nakamura Y; Yasuoka H; Kodama R
Gan To Kagaku Ryoho; 2009 Apr; 36(4):611-4. PubMed ID: 19381033
[TBL] [Abstract][Full Text] [Related]
14. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response.
Felip E; Rosell R
Expert Rev Mol Diagn; 2007 May; 7(3):261-8. PubMed ID: 17489733
[TBL] [Abstract][Full Text] [Related]
15. [Correlation between expression of excision repair cross-complementing 1 and cisplatin sensitivity in non-small cell lung cancer].
Han XP; Zhang X
Zhonghua Yi Xue Za Zhi; 2010 Aug; 90(30):2115-8. PubMed ID: 21029626
[TBL] [Abstract][Full Text] [Related]
16. The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC.
Cai Y; Yan X; Zhang G; Zhao W; Jiao S
Oncotarget; 2015 Aug; 6(22):18997-9005. PubMed ID: 25944617
[TBL] [Abstract][Full Text] [Related]
17. [Examination of ERCC1 expression in lung cancer patients treated with platinum-based chemotherapy].
Moldvay J; Pápay J; Puskás R; Furák J; Losonczy G; Matolcsy A
Magy Onkol; 2011 Jun; 55(2):105-9. PubMed ID: 21655476
[TBL] [Abstract][Full Text] [Related]
18. [ERCC1 and lung cancer].
Planchard D; Olaussen KA; Soria JC
Rev Mal Respir; 2010 Apr; 27(4):387-94. PubMed ID: 20403548
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect?
Besse B; Le Chevalier T
J Clin Oncol; 2008 Nov; 26(31):5014-7. PubMed ID: 18809602
[No Abstract] [Full Text] [Related]
20. Expression of p21 and bcl-2 proteins in paraffin-embedded preparations of non-small cell lung cancer in stage IIIA after Etoposide and Cisplatin induced chemotherapy.
Mańdziuk S; Dudzisz-Sledź M; Korszeń-Pilecka I; Milanowski J; Wojcierowski J; Korobowicz E
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):149-53. PubMed ID: 15314975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]